MCID: HST010
MIFTS: 60

Histiocytosis

Categories: Immune diseases, Cancer diseases, Respiratory diseases, Bone diseases, Blood diseases, Rare diseases

Aliases & Classifications for Histiocytosis

MalaCards integrated aliases for Histiocytosis:

Name: Histiocytosis 12 51 41 14 69
Chronic Multifocal Langerhans Cell Histiocytosis 55
Multifocal Eosinophilic Granuloma 55
Hand Schuller Christian Disease 12
Hand-Schüller-Christian Disease 55
Histiocytosis, Langerhans-Cell 69
Chronic Histiocytosis X 12
Histiocytic Syndrome 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3405
MeSH 41 D015614
NCIt 46 C3106
Orphanet 55 ORPHA99873
ICD10 via Orphanet 33 C96.5

Summaries for Histiocytosis

Disease Ontology : 12 A lymphatic system disease that is characterized by an excessive number of histiocytes.

MalaCards based summary : Histiocytosis, also known as chronic multifocal langerhans cell histiocytosis, is related to alk+ histiocytosis and erdheim-chester disease, and has symptoms including proptosis, diabetes insipidus and pulmonary infiltrates. An important gene associated with Histiocytosis is SLC29A3 (Solute Carrier Family 29 Member 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and lung, and related phenotypes are cellular and hematopoietic system

Wikipedia : 72 In medicine, histiocytosis refers to an excessive number of histiocytes, (tissue macrophages), and is... more...

Related Diseases for Histiocytosis

Diseases in the Histiocytosis family:

Malignant Histiocytosis

Diseases related to Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 386)
# Related Disease Score Top Affiliating Genes
1 alk+ histiocytosis 33.5 CD1A CD207 FSCN1
2 erdheim-chester disease 32.8 BRAF SERPINA3
3 malignant histiocytosis 32.7 CSF1R SERPINA3 TNFRSF8
4 juvenile xanthogranuloma 32.6 BRAF FSCN1 S100B
5 non-langerhans-cell histiocytosis 32.6 BRAF CD163 CD207 IL1RN SMPD1
6 langerhans cell sarcoma 32.5 CD1A CD207
7 langerhans cell histiocytosis 32.3 BRAF CD101 CD163 CD1A CD207 CSF2
8 rosai-dorfman disease 31.7 CD163 FSCN1 S100B SLC29A3 STAB1
9 dendritic cell tumor 31.4 CD1A CD207 FSCN1 PTPRC S100B
10 reticulohistiocytic granuloma 30.0 CD163 CD207 FSCN1 PTPRC SERPINA3 TNFRSF8
11 histiocytoma 29.7 CD163 PTPRC SERPINA3
12 myeloma, multiple 29.7 BRAF CSF2 PTPRC
13 leukemia, acute myeloid 29.4 CSF1R CSF2 ITGAX PTPRC
14 interdigitating dendritic cell sarcoma 29.4 CD163 PTPRC
15 anaplastic large cell lymphoma 29.3 CSF1R PTPRC TNFRSF8
16 histiocytic sarcoma 29.3 BRAF CD163 CSF1R FSCN1 S100B
17 lymphoma, hodgkin, classic 29.1 CSF2 FSCN1 PTPRC TNFRSF8
18 lymphoma, non-hodgkin, familial 28.6 BRAF CSF2 ITGAX PTPRC TNFRSF8
19 histiocytosis-lymphadenopathy plus syndrome 12.5
20 histiocytosis, progressive mucinous 12.3
21 benign cephalic histiocytosis 12.3
22 generalized eruptive histiocytosis 12.3
23 indeterminate cell histiocytosis 12.3
24 progressive nodular histiocytosis 12.2
25 adult pulmonary langerhans cell histiocytosis 12.2
26 sea-blue histiocyte disease 12.1
27 hashimoto-pritzker syndrome 12.0
28 histiocytosis, familial lipochrome 11.8
29 eosinophilic granuloma 11.8
30 letterer-siwe disease 11.6
31 gaucher's disease 11.4
32 niemann-pick disease 11.4
33 necrobiotic xanthogranuloma 11.1
34 papular xanthoma 11.1
35 hemophagocytic lymphohistiocytosis 11.1
36 interstitial lung disease 11.1
37 dentin dysplasia, type i 10.8
38 dysosteosclerosis 10.8
39 infantile myofibromatosis 10.8
40 omenn syndrome 10.8
41 polymorphic reticulosis 10.8
42 primary cutaneous anaplastic large cell lymphoma 10.8
43 tumor suppressor gene on chromosome 11 10.4 BRAF MAP2K1
44 lymphoma 10.4
45 xanthoma disseminatum 10.4
46 myopericytoma 10.4 BRAF S100B
47 malignant giant cell tumor of soft parts 10.3 PTPRC S100B
48 syringocystadenoma papilliferum 10.3 BRAF S100B
49 cavernous sinus meningioma 10.3 CD163 CD207
50 nodular tenosynovitis 10.3 PTPRC SERPINA3

Graphical network of the top 20 diseases related to Histiocytosis:



Diseases related to Histiocytosis

Symptoms & Phenotypes for Histiocytosis

Human phenotypes related to Histiocytosis:

55 31 (show all 7)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 proptosis 55 31 hallmark (90%) Very frequent (99-80%) HP:0000520
2 diabetes insipidus 55 31 hallmark (90%) Very frequent (99-80%) HP:0000873
3 pulmonary infiltrates 55 31 occasional (7.5%) Occasional (29-5%) HP:0002113
4 hepatomegaly 55 31 occasional (7.5%) Occasional (29-5%) HP:0002240
5 lymphadenopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0002716
6 osteolysis 55 31 hallmark (90%) Very frequent (99-80%) HP:0002797
7 papule 55 31 occasional (7.5%) Occasional (29-5%) HP:0200034

MGI Mouse Phenotypes related to Histiocytosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 SMPD1 CD163 CSF1R CSF2 FSCN1 IL1RN
2 hematopoietic system MP:0005397 9.73 CD101 TNFRSF8 CD163 CD207 CSF1R CSF2
3 immune system MP:0005387 9.44 CD101 TNFRSF8 CD163 CD207 CSF1R CSF2

Drugs & Therapeutics for Histiocytosis

Drugs for Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 657311 5754
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
10
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
11
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
13
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
14
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
15
Vinblastine Approved Phase 3,Phase 2 865-21-4 241903 13342
16
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
17
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
18
Cytarabine Approved, Investigational Phase 2, Phase 3 147-94-4 6253
19
Indomethacin Approved, Investigational Phase 2, Phase 3 53-86-1 3715
20
Asparaginase Approved, Investigational Phase 3 9015-68-3
21
Pegaspargase Approved, Investigational Phase 3 130167-69-0
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
23
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
24
Butyric Acid Experimental, Investigational Phase 3,Phase 2 107-92-6 264
25
Doxil Approved June 1999 Phase 3,Phase 2 31703
26
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
27 Alkylating Agents Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
29 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
30 Antiemetics Phase 3,Phase 2,Phase 1
31 Antifungal Agents Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
34 Antilymphocyte Serum Phase 3,Phase 2,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
39 Antirheumatic Agents Phase 3,Phase 2,Phase 1
40 Antitubercular Agents Phase 3,Phase 2,Phase 1
41 Autonomic Agents Phase 3,Phase 2,Phase 1
42 BB 1101 Phase 3,Phase 2
43 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1
44 Cortisol succinate Phase 3,Phase 2
45 Cyclosporins Phase 3,Phase 2,Phase 1
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
48 Etoposide phosphate Phase 3,Phase 2
49 Folic Acid Antagonists Phase 3,Phase 2
50 Gastrointestinal Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 126)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
2 H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis Completed NCT00488605 Phase 3 Prednisone, Vinblastin, 6-mercaptopuroine;Leucovorin, Methotrexate, Vinblastine, Prednisone
3 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
4 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
5 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Recruiting NCT02205762 Phase 2, Phase 3 Prednisone;Vinblastine;mercaptopurine;INDOMETHACIN;Methotrexate;Cytosine Arabinoside;2-chlorodeoxyadenosine
6 Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) Recruiting NCT02670707 Phase 3 Cytarabine;Vinblastine/prednisone
7 L-DEP as an Initial Treatment for EBV-HLH Recruiting NCT02912702 Phase 3 Pegaspargase;doxorubicin hydrochloride liposome injection;etoposide;methylprednisolone;Etoposide;dexamethasone
8 Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Recruiting NCT02862054 Phase 2, Phase 3
9 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Recruiting NCT02631109 Phase 3 Pegaspargase;doxorubicin;etoposide;methylprednisolone
10 A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT01818492 Phase 2, Phase 3
11 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
12 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Active, not recruiting NCT00426101 Phase 3 Dexamethasone;Etoposide;Cyclosporin
13 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
14 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
15 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Not yet recruiting NCT03312751 Phase 3 Emapalumab
16 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
17 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
18 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
19 Trial of DA-EPOCH Regimen for NHL With HLH Unknown status NCT01818908 Phase 2 DA-EPOCH
20 Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL Completed NCT00048373 Phase 2 Etanercept
21 A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis Completed NCT01395004 Phase 2 GSK2110183
22 Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH Completed NCT00588536 Phase 2 Methotrexate;6-Thioguanine;Leucovorin Calcium
23 HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Completed NCT00145626 Phase 2 Chemotherapy and antibodies
24 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
25 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
26 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Completed NCT01104025 Phase 2 ATG, rabbit;Etoposide;Methotrexate;hydrocortisone;Dexamethasone
27 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
28 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
29 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
30 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
31 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
32 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis Recruiting NCT02425904 Phase 2 Clofarabine
33 Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis Recruiting NCT02389400 Phase 2 methotrexate
34 Denosumab for the Treatment of Adult LCH Recruiting NCT03270020 Phase 2 Denosumab 70 MG/ML [Xgeva]
35 A Study of Lenalidomide for Adult Histiocyte Disorders Recruiting NCT02523040 Phase 2 Lenalidomide
36 Single-agent Cobimetinib for Adults With Histiocytic Disorders Recruiting NCT02649972 Phase 2 Cobimetinib
37 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
38 Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
39 Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations Recruiting NCT03213665 Phase 2 Tazemetostat
40 Pediatric MATCH: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations Recruiting NCT03210714 Phase 2 Erdafitinib
41 Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
42 Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib
43 Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
44 Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations Recruiting NCT03213691 Phase 2 Selumetinib
45 Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
46 Treatment of Familiar Lymphohistiocytosis Recruiting NCT02472054 Phase 1, Phase 2 Alemtuzumab;Methyl Prednisolone (MP);Cyclosporin A (CSA)
47 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting NCT02385110 Phase 2 Alemtuzumab;Etoposide;Dexamethasone;Methotrexate;Tocilizumab
48 Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting NCT02007239 Phase 2 tocilizumab
49 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting NCT02061800 Phase 1, Phase 2 Thiotepa;Cyclophosphamide;Alemtuzumab;Tacrolimus;Melphalan;Busulfan;Fludarabine;Methylprednisolone
50 A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) Recruiting NCT03311854 Phase 2 NI-0501

Search NIH Clinical Center for Histiocytosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: histiocytosis

Genetic Tests for Histiocytosis

Anatomical Context for Histiocytosis

MalaCards organs/tissues related to Histiocytosis:

38
Bone, T Cells, Lung, Thyroid, Bone Marrow, Skin, Liver

Publications for Histiocytosis

Articles related to Histiocytosis:

(show top 50) (show all 1594)
# Title Authors Year
1
An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. ( 29355432 )
2018
2
Reconstruction of a severe mandibular pathological fracture caused by Langerhans cell histiocytosis using a free fibula osteocutaneous flap:a case report. ( 29372175 )
2018
3
Cutaneous manifestations of paediatric Erdheim-Chester disease, a histiocytosis of the 'L' group. ( 29357606 )
2018
4
Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib. ( 29379859 )
2018
5
Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations. ( 29341328 )
2018
6
Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement. ( 29413280 )
2018
7
Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. ( 29428448 )
2018
8
Crystal-Storing Histiocytosis in Bone Marrow: A Clinicopathologic Study of Eight Cases and Review of the Literature. ( 29385417 )
2018
9
Reflectance Confocal Microscopy for the Diagnosis of Langerhans Cell Histiocytosis. ( 29341062 )
2018
10
Congenital Langerhans cell histiocytosis presenting in a 27-week-gestation neonate. ( 29436047 )
2018
11
Intraoperative MRI-guided biopsy in the diagnosis of suprasellar Langerhans Cell Histiocytosis. ( 29317365 )
2018
12
Generalized eruptive histiocytosis diagnosed in light of dermoscopic findings. ( 29243820 )
2018
13
Benign cephalic histiocytosis: A case with infiltration of CD1a-positive langerin-negative cells. ( 29430698 )
2018
14
RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. ( 29263218 )
2018
15
Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL. ( 29264111 )
2018
16
Classic Hodgkin lymphoma with osseous involvement mimicking Langerhans cell histiocytosis in a child. ( 29307624 )
2018
17
Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. ( 28220299 )
2017
18
Fever and Skin Involvement at Diagnosis Predicting the Intractable Langerhans Cell Histiocytosis: 40 Case-Series in a Single Center. ( 29293189 )
2017
19
Langerhans Cell Histiocytosis Presenting as Chronic Otitis Externa. ( 28045847 )
2017
20
Adult Langerhans cell histiocytosis with pulmonary and colorectoanal involvement: a case report. ( 28942734 )
2017
21
New classification of histiocytosis. ( 28919209 )
2017
22
CD207(+)CD1a(+) cells circulate in pediatric patients with active Langerhans cell histiocytosis. ( 28847997 )
2017
23
Indeterminate cell histiocytosis: a case series and review of the literature. ( 28943499 )
2017
24
Indeterminate cell histiocytosis: A case treated with ultraviolet b narrow band phototherapy (NB UVB). ( 28661557 )
2017
25
Novel Clinical Observations on Benign Cephalic Histiocytosis in a Large Series. ( 28466548 )
2017
26
Progressive nodular histiocytosis improved by methotrexate. ( 29165296 )
2017
27
Langerhans Cell Histiocytosis With Clinical and Histologic Features of Hidradenitis Suppurativa: Brief Report and Review. ( 28937439 )
2017
28
Cutaneous Indeterminate Cell Histiocytosis of Donor Origin After Allogeneic Hematopoietic Stem-Cell Transplantation. ( 28825606 )
2017
29
Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. ( 28944988 )
2017
30
Dermoscopy of Langerhans cell histiocytosis. ( 28087041 )
2017
31
Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. ( 28084334 )
2017
32
A Case with Juvenile Xanthogranuloma and Progressive Nodular Histiocytosis Overlap. ( 28297144 )
2017
33
A Case of Pulmonary Langerhans Cell Sarcoma Simultaneously Diagnosed with Cutaneous Langerhans Cell Histiocytosis Studied by Whole-Exome Sequencing. ( 28614815 )
2017
34
Langerhans cell histiocytosis of the thyroid complicated by papillary thyroid carcinoma: A case report and brief literature review. ( 28858125 )
2017
35
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults. ( 28512190 )
2017
36
Indeterminate Cell Histiocytosis Presenting with Leonine Facies. ( 29243769 )
2017
37
Autopsy Findings in A Case of Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. ( 29301140 )
2017
38
Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus. ( 28889238 )
2017
39
Targeting BRAK, MEK, mTOR, and now AKT in histiocytosis: The ongoing revolution of therapies in orphan diseases. ( 28066975 )
2017
40
Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis. ( 28072848 )
2017
41
Atlanto-axial langerhans cell histiocytosis in a child presented as torticollis. ( 28868307 )
2017
42
Langerhans cell histiocytosis (eosinophilic granuloma) of the skull mimicking nummular headache. Report of two cases. ( 28490189 )
2017
43
Cerebellar Disease Mimicking Cerebrotendinous Xanthomatosis: Langerhans Cell Histiocytosis. ( 28554492 )
2017
44
Congenital Self Healing Langerhans Cell Histiocytosis. ( 28929464 )
2017
45
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. ( 29188284 )
2017
46
How I manage pulmonary Langerhans cell histiocytosis. ( 28877978 )
2017
47
Griscelli syndrome subtype 2 with hemophagocytic lympho-histiocytosis: A case report and review of literature. ( 28357189 )
2017
48
Langerhans cell histiocytosis in an adult female presenting with widespread confluent crusted papules and review of adult cases confined to skin. ( 28880370 )
2017
49
Pulmonary langerhans cell histiocytosis - insight into the incidence of alfa-1-antitrypsin (A1ATD) deficiency alleles. ( 29288477 )
2017
50
Demodicosis in two patients with a previous history of Langerhans cell histiocytosis. ( 28940244 )
2017

Variations for Histiocytosis

Expression for Histiocytosis

Search GEO for disease gene expression data for Histiocytosis.

Pathways for Histiocytosis

GO Terms for Histiocytosis

Cellular components related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.44 BRAF CD101 CD163 CD1A CD207 CSF1R

Biological processes related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 face development GO:0060324 9.32 BRAF MAP2K1
2 monocyte differentiation GO:0030224 9.26 CSF1R CSF2
3 positive regulation of podosome assembly GO:0071803 9.16 CSF2 FSCN1
4 inflammatory response GO:0006954 9.1 CD163 CSF1R IL1RN SERPINA3 STAB1 TNFRSF8
5 regulation of axon regeneration GO:0048679 8.96 BRAF MAP2K1

Molecular functions related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 BRAF CD163 CD1A CD207 CSF1R CSF2

Sources for Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....